Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998051344) SUPPRESSION OF TUMOR NECROSIS FACTOR ALPHA AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN THERAPY
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/051344 International Application No.: PCT/GB1998/001343
Publication Date: 19.11.1998 International Filing Date: 12.05.1998
Chapter 2 Demand Filed: 19.11.1998
IPC:
A61K 31/00 (2006.01) ,A61K 39/395 (2006.01) ,C07K 16/24 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
Applicants:
THE KENNEDY INSTITUTE OF RHEUMATOLOGY [GB/GB]; One Aspenlea Road Hammersmith London W6 8LH, GB
Inventors:
FELDMANN, Marc; GB
MAINI, Ravinder, Nath; US
PALEOLOG, Ewa, Maria; GB
Agent:
HARVEY, David, Gareth ; Graham Watt & Co. Riverhead Sevenoaks Kent TN13 2BN, GB
Priority Data:
08/854,88112.05.1997US
Title (EN) SUPPRESSION OF TUMOR NECROSIS FACTOR ALPHA AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN THERAPY
(FR) SUPPRESSION THERAPEUTIQUE DU FACTEUR DE NECROSE TUMORALE ALPHA ET DU FACTEUR DE CROISSANCE DES CELLULES ENDOTHELIALES VASCULAIRES
Abstract:
(EN) Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed are compositions comprising a TNF$g(a) antagonist and a VEGF antagonist. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.
(FR) L'invention concerne des procédés permettant de traiter et/ou d'empêcher une maladie associée au facteur de nécrose tumorale (TNF) chez un individu. L'invention concerne également des compositions contenant un antagoniste du TNF$g(a) et un antagoniste du facteur de croissance des cellules endothéliales vasculaires (VEGF). Parmi les maladies médiées par le TNF on trouve la polyarthrite rhumatoïde, la maladie de Crohn ainsi que des troubles immunologiques aigus et chroniques associés à une greffe.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0980258EP1170017JP2001525816 CA2290021AU1998073457